Aileron Therapeutics Future Growth
Future criteria checks 0/6
Aileron Therapeutics's earnings are forecast to decline at 2.9% per annum. EPS is expected to grow by 3.4% per annum.
Key information
-2.9%
Earnings growth rate
3.4%
EPS growth rate
| Biotechs earnings growth | 26.8% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Nov 2024 |
Recent future growth updates
Recent updates
Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky
Aug 18
Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?
Dec 30Aileron Therapeutics: An Assessment On A Lottery Ticket
Oct 21Aileron Therapeutics: Solving Chemotherapy's Toxicity
May 01Aileron Therapeutics +31% on insider buying more shares
Jan 08Aileron raises $40M via equity offering
Jan 06Aileron Therapeutics EPS in-line
Nov 13Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | N/A | -52 | N/A | N/A | 2 |
| 12/31/2026 | N/A | -43 | N/A | N/A | 2 |
| 12/31/2025 | N/A | -36 | N/A | N/A | 2 |
| 12/31/2024 | N/A | -24 | N/A | N/A | 2 |
| 9/30/2024 | N/A | -29 | -28 | -28 | N/A |
| 6/30/2024 | N/A | -25 | -26 | -26 | N/A |
| 3/31/2024 | N/A | -18 | -20 | -20 | N/A |
| 12/31/2023 | N/A | -16 | -20 | -20 | N/A |
| 9/30/2023 | N/A | -13 | -14 | -14 | N/A |
| 6/30/2023 | N/A | -17 | -19 | -19 | N/A |
| 3/31/2023 | N/A | -24 | -22 | -22 | N/A |
| 12/31/2022 | N/A | -27 | -25 | -25 | N/A |
| 9/30/2022 | N/A | -30 | -27 | -27 | N/A |
| 6/30/2022 | N/A | -30 | -27 | -27 | N/A |
| 3/31/2022 | N/A | -28 | -25 | -25 | N/A |
| 12/31/2021 | N/A | -26 | -24 | -24 | N/A |
| 9/30/2021 | N/A | -24 | -22 | -22 | N/A |
| 6/30/2021 | N/A | -23 | -20 | -20 | N/A |
| 3/31/2021 | N/A | -21 | -21 | -21 | N/A |
| 12/31/2020 | N/A | -21 | -20 | -20 | N/A |
| 9/30/2020 | N/A | -23 | -22 | -22 | N/A |
| 6/30/2020 | N/A | -26 | -24 | -24 | N/A |
| 3/31/2020 | N/A | -29 | -25 | -25 | N/A |
| 12/31/2019 | N/A | -29 | -27 | -26 | N/A |
| 9/30/2019 | N/A | -29 | -29 | -27 | N/A |
| 6/30/2019 | N/A | -29 | -31 | -27 | N/A |
| 3/31/2019 | N/A | -31 | -33 | -28 | N/A |
| 12/31/2018 | N/A | -32 | -32 | -28 | N/A |
| 9/30/2018 | N/A | -31 | -30 | -27 | N/A |
| 6/30/2018 | N/A | -30 | N/A | -25 | N/A |
| 3/31/2018 | N/A | -26 | N/A | -22 | N/A |
| 12/31/2017 | N/A | -23 | N/A | -21 | N/A |
| 9/30/2017 | N/A | -20 | N/A | -19 | N/A |
| 6/30/2017 | N/A | -18 | N/A | -18 | N/A |
| 3/31/2017 | N/A | -19 | N/A | -17 | N/A |
| 12/31/2016 | N/A | -18 | N/A | -15 | N/A |
| 9/30/2016 | N/A | -17 | N/A | -14 | N/A |
| 6/30/2016 | N/A | -16 | N/A | -12 | N/A |
| 3/31/2016 | N/A | -14 | N/A | -12 | N/A |
| 12/31/2015 | N/A | -13 | N/A | -12 | N/A |
| 9/30/2015 | N/A | -13 | N/A | -13 | N/A |
| 6/30/2015 | N/A | -13 | N/A | -12 | N/A |
| 3/31/2015 | N/A | -15 | N/A | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALRN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALRN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALRN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if ALRN's revenue is forecast to grow faster than the US market.
High Growth Revenue: ALRN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALRN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/12 03:58 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aileron Therapeutics, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ying Huang | BofA Global Research |
| Brian Kemp Dolliver | Brookline Capital Markets |
| John Newman | Canaccord Genuity |